Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Universal Ibogaine Inc ( (TSE:IBO) ) has issued an announcement.
Universal Ibogaine Inc. announced changes to its Board of Directors, with several members resigning and a new board confirmed as the company prepares to submit its clinical trial application to Health Canada by November 2025. This strategic move is part of Universal Ibogaine’s broader mission to revolutionize addiction treatment, particularly for opioid use disorder, and to strengthen its position in the life sciences industry.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a life sciences company focused on transforming addiction treatment through medicalized ibogaine. The company is planning a Canadian clinical trial targeting opioid use disorder and aims to expand its treatment protocol globally through future licensing agreements. Additionally, Universal Ibogaine is developing a holistic addiction treatment protocol at its Kelburn Recovery Centre in Manitoba.
Average Trading Volume: 323,025
Technical Sentiment Signal: Sell
Current Market Cap: C$4.12M
See more data about IBO stock on TipRanks’ Stock Analysis page.